Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selpercatinib in RET-Altered Cancers in India
NCT07822880Phase 4Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2026
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
A Phase 4 trial of selpercatinib in non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC), thyroid cancer, solid tumor, sponsored by Eli Lilly and Company. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
selpercatinib
03
Conditions
non-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)thyroid cancersolid tumor
Beyond the preview
Go deeper on NCT07822880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07822880.